Debbie Rigby rounds up the latest in research news
A large population-based cohort study using US-based databases has shown that the risk for severe and nonsevere UTI events among those initiating SGLT-2 inhibitor therapy was similar to that among patients initiating treatment with other second-line antidiabetic medications. The incident rate for severe UTIs in patients taking SGLT-2 inhibitors was 1.76 per 1000 person-years, compared to 1.77 in the DPP-4 inhibitor group; similar rates were observed compared to GLP-1 agonists (IR 2.15 vs 2.96) In addition, SGLT-2 inhibitors were not associated with increased risk for outpatient UTIs.
Ann Intern Med. 2019;171(4):248-256.
In this prospective, randomized trial of 532 patients with COPD the time until the first COPD exacerbation was similar in the extended-release metoprolol group and the placebo group. Hospitalization for exacerbation was more common among the patients treated with metoprolol.
N Engl J Med 2019; 381:2304-2314.
Three large cardiovascular outcomes trials have demonstrated consistent reductions in heart failure events among patients with type 2 diabetes mellitus with, or at risk for, atherosclerotic cardiovascular disease. Another trial recently showed that an SGLT2 inhibitor, canagliflozin, also significantly reduced heart failure events among patients with type 2 diabetes mellitus and albuminuric chronic kidney disease.
Am J Cardiol 2019;124:S20−S27
Green tea with its polyphenols can lead to potentially lead to serious drug interactions. Clinically significant drug interactions may occur with tacrolimus and warfarin. No clinically relevant drug interactions were reported for digoxin, sildenafil, simvastatin, and rosuvastatin.
Expert Opinion on Drug Metabolism & Toxicology, 2019;15(12):989-991.